Core Viewpoint - Healthpeak (DOC) is undervalued in the market, particularly regarding its senior housing assets, which are being spun off into a new entity, Janus Living (JAN), to unlock their true value [1][2][29]. Valuation Overview - Healthpeak's property valuation includes $10.5 billion in medical office buildings (MOBs), $8.8 billion in labs, and approximately $3 billion in senior housing [3]. - The senior housing portfolio is believed to be worth $4.25 billion, significantly higher than the $3 billion recorded on the books [2][12]. Market Comparisons - The market multiples for different property sectors show that labs trade at the lowest multiples, while senior housing commands the highest [5][8]. - Healthpeak trades at 11.3X AFFO, which is between the multiples for labs (10.3X) and MOBs (14.6X), indicating a lack of recognition for its senior housing assets [8][11]. Upcoming IPO Details - The IPO for Janus Living is targeting a price range of $18-$20 per share, with strong investor interest already indicated [13][14]. - The offering aims to raise approximately $635.5 million in net proceeds, with Healthpeak retaining a significant ownership stake in Janus [15][17]. Financial Metrics - The implied valuation of Janus at the midpoint offering price of $19 suggests a total value of approximately $4.79 billion, with senior housing assets valued at around $4.26 billion after accounting for cash and debt [19][21]. - The pro forma estimated NOI for the senior housing portfolio is $199.6 million, with an AFFO of $170 million [25]. Future Growth Potential - Janus Living is expected to utilize IPO proceeds for immediate acquisitions, positioning it for growth [30]. - Healthpeak will benefit from the value appreciation of Janus shares, which will be held on its balance sheet for at least a year due to lock-up provisions [32].

Core Insights - Healthpeak Properties, Inc. (DOC) is a publicly traded real estate investment trust (REIT) with a market cap of $11.6 billion, focusing on a diversified portfolio of healthcare properties [1][2] Company Overview - DOC is classified as a large-cap stock, emphasizing its significant size and influence in the healthcare REIT sector [2] - The company specializes in high-quality healthcare assets that benefit from long-term leases and stable cash flows [2] Stock Performance - DOC's stock has decreased by 21.9% from its 52-week high of $21.28, reached on March 10, and has underperformed the Dow Jones Industrial Average (DOWI) [3][4] - Over the past three months, DOC shares have declined by 8.1%, while DOWI has risen by 5.7% [3] - In the last 52 weeks, DOC has fallen by 20.6%, compared to DOWI's increase of 10.4% [4] - The stock has been trading below its 200-day moving average since late October and has recently dipped below its 50-day moving average [4] Financial Performance - In the third quarter, Healthpeak reported total revenue of approximately $705.9 million, slightly exceeding expectations, supported by stable outpatient medical and lab leasing activity [5] - The company generated Nareit FFO of about $0.45 per share and Adjusted FFO of $0.46, aligning with guidance [5] - Healthpeak recorded a net loss of roughly $0.17 per share, primarily due to equity losses from unconsolidated ventures, which affected diluted EPS [5] - Occupancy trends were mixed, with rising outpatient medical demand but pressure on lab occupancy [5] Competitive Position - Healthpeak's underperformance is notable when compared to its competitor, Omega Healthcare Investors, Inc. (OHI), which has seen a 13.3% rise over the past 52 weeks and an 18.8% increase over the past six months [6]